GMED Stock Analysis: Globus Medical | NYSE
Medical Devices | NYSE, USA | Market Cap: 10.876m USD | 12M Return: 35.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 148M
EPS Trend: 98.1%
Qual. Beats: 4
Rev. Trend: 93.0%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Globus Medical (NYSE: GMED) is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders, operating in the United States and internationally. The company was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
The companys product portfolio spans spine solutions (including traditional fusion implants, motion preservation technologies, interventional treatments for vertebral compression fractures, and biologic solutions), orthopedic trauma offerings, and hip and knee arthroplasty systems. It also provides spinal cord stimulation and intraoperative neuromonitoring services, and distributes human cell and tissue-based products.
Globus Medical has invested heavily in surgical robotics and navigation, with its Excelsius platform family-including ExcelsiusGPS, Excelsius3D, ExcelsiusHub, and the ExcelsiusFlex total knee arthroplasty solution-alongside its Surgimap surgical planning software. Products are sold through a mix of direct sales representatives, distributors, and independent sales agents.
As a Large Cap stock within the Health Care Equipment sub-industry, GMED operates in the global orthopedic and spine device market, where robotic-assisted surgery and enabling technologies represent an increasingly important growth segment alongside traditional implant sales.
- NuVasive merger integration unlocks cross-selling synergies in spine
- ExcelsiusGPS robotic platform adoption accelerates hospital wins
- Deleveraging from NuVasive deal limits capital allocation flexibility
| Net Income: 586.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 0.05 > 1.0 |
| NWC/Revenue: 55.33% < 20% (prev 52.79%; Δ 2.54% < -1%) |
| CFO/TA 0.14 > 3% & CFO 778.5m > Net Income 586.7m |
| Net Debt (-514.6m) to EBITDA (879.9m): -0.58 < 3 |
| Current Ratio: 4.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (138.2m) vs 12m ago -1.13% < -2% |
| Gross Margin: 67.86% > 18% (prev 60.59%; Δ 7.27% > 0.5%) |
| Asset Turnover: 61.09% > 50% (prev 53.30%; Δ 7.80% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.32 (Total Current Assets 2.20b - Total Current Liabilities 482.5m) / Total Assets 5.44b |
| B: 0.28 (Retained Earnings 1.51b / Total Assets 5.44b) |
| C: 0.12 (EBIT TTM 597.9m / Avg Total Assets 5.08b) |
| D: 6.69 (Book Value of Equity 4.73b / Total Liabilities 707.2m) |
| Altman-Z'' = 10.79 = AAA |
| DSRI: 1.11 (Receivables 735.4m/538.1m, Revenue 3.10b/2.51b) |
| GMI: 0.89 (GM 60.59% / 67.86%) |
| AQI: 0.95 (AQ_t 0.48 / AQ_t-1 0.51) |
| SGI: 1.23 (Revenue 3.10b / 2.51b) |
| TATA: -0.04 (NI 586.7m - CFO 778.5m) / TA 5.44b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 78.11 with a total of 1,549,543 shares traded. Over the past week, the price has changed by -2.51%, over one month by -3.40%, over three months by -13.61% and over the past year by +35.14%.
Current recommended Stop Loss: 72.10 (which is 7.7% or 1.8 ATR below the current price).
Globus Medical has received a consensus analysts rating of 3.93. Therefore, it is recommended to buy GMED.
- StrongBuy: 4
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 108.6 | 39.1% |
P/E Trailing = 18.7196
P/E Forward = 17.6367
P/S = 3.5076
P/B = 2.2982
P/EG = 1.4934
Revenue TTM = 3.10b USD
EBIT TTM = 597.9m USD
EBITDA TTM = 879.9m USD
Long Term Debt = 100.1m USD (estimated: total debt 115.2m - short term 15.1m)
Short Term Debt = 15.1m USD (from shortTermDebt, last quarter)
Debt = 115.2m USD (from shortLongTermDebtTotal, last quarter) (leases 115.2m already included)
Net Debt = -514.6m USD (calculated: Debt 115.2m - CCE 629.9m)
Enterprise Value = 10.4b USD (10.9b + Debt 115.2m - CCE 629.9m)
Interest Coverage Ratio = unknown (Ebit TTM 597.9m / Interest Expense TTM 0.0)
EV/FCF = 17.26x (Enterprise Value 10.4b / FCF TTM 600.3m)
FCF Yield = 5.79% (FCF TTM 600.3m / Enterprise Value 10.4b)
FCF Margin = 19.36% (FCF TTM 600.3m / Revenue TTM 3.10b)
Net Margin = 18.92% (Net Income TTM 586.7m / Revenue TTM 3.10b)
Gross Margin = 67.86% ((Revenue TTM 3.10b - Cost of Revenue TTM 996.5m) / Revenue TTM)
Gross Margin QoQ = 69.20% (prev 72.02%)
Tobins Q-Ratio = 1.90 (Enterprise Value 10.4b / Total Assets 5.44b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 115.2m)
Taxrate = 11.54% (76.6m / 663.3m)
NOPAT = 528.9m (EBIT 597.9m * (1 - 11.54%))
Current Ratio = 4.56 (Total Current Assets 2.20b / Total Current Liabilities 482.5m)
Debt / Equity = 0.02 (Debt 115.2m / totalStockholderEquity, last quarter 4.73b)
Debt / EBITDA = -0.58 (Net Debt -514.6m / EBITDA 879.9m)
Debt / FCF = -0.86 (Net Debt -514.6m / FCF TTM 600.3m)
Total Stockholder Equity = 4.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.56% (Net Income 586.7m / Total Assets 5.44b)
RoE = 13.04% (Net Income TTM 586.7m / Total Stockholder Equity 4.50b)
RoCE = 13.00% (EBIT 597.9m / Capital Employed (Equity 4.50b + L.T.Debt 100.1m))
RoIC = 10.98% (NOPAT 528.9m / Invested Capital 4.82b)
WACC = 7.42% (E(10.9b)/V(11.0b) * Re(7.50%) + D(115.2m)/V(11.0b) * Rd(0.0%) * (1-Tc(0.12)))
Discount Rate = 7.50% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 6.67 | Cagr: -0.27%
[DCF] Terminal Value 77.97% ; FCFF base≈567.2m ; Y1≈650.2m ; Y5≈957.0m
[DCF] Fair Price = 131.6 (EV 14.4b - Net Debt -514.6m = Equity 14.9b / Shares 113.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.08 | EPS CAGR: 27.05% | SUE: 1.52 | # QB: 4
Revenue Correlation: 93.01 | Revenue CAGR: 42.38% | SUE: 0.98 | # QB: 2
EPS current Quarter (2026-06-30): EPS=1.10 | Chg30d=+0.02% | Revisions=+69% | Analysts=13
EPS next Quarter (2026-09-30): EPS=1.17 | Chg30d=+0.44% | Revisions=+31% | Analysts=13
EPS current Year (2026-12-31): EPS=4.74 | Chg30d=+0.39% | Revisions=+82% | GrowthEPS=+19.2% | GrowthRev=+9.0%
EPS next Year (2027-12-31): EPS=5.15 | Chg30d=+0.05% | Revisions=+82% | GrowthEPS=+8.5% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: +77% (up=49, down=5)